Thermo Fisher Scientific will invest over $140m in the manufacture and growth of vaccines and therapies

Recently, Thermo Fisher Scientific reported that it is investing over one hundred and forty million dollars in the manufacture and growth of vaccines and therapies, as well as in the further expansion of its production of laboratory plastic consumables, to meet the growing demand for COVID-19 research worldwide.

Historic demand for laboratory plastics has been generated by the increased production related to COVID-19 research, development and production of vaccines and therapies. As a result, Thermo Fisher Scientific is leveraging the capacity of warehouses and sterilisation to enhance the agility of the supply chain and generate over one thousand jobs at manufacturing sites around the world.

Senior Vice President and President of Life Sciences Solutions and Laboratory Products, Thermo Fisher Scientific, Fred Lowery, stated: “Early in the pandemic, we quickly joined forces with governments, public health agencies and industry to increase capacity across our laboratory plastics production facilities and address the growing COVID-19 threat. However, demand quickly exceeded those early expansion projects, so we began a series of additional expansions to meet the growing needs of our customers. These investments, along with many others across the company, will ensure that our customers have the supplies they need to continue meeting the unprecedented demands of the COVID-19 response.”